X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Collaboration with BARDA for the development of TEMBEXA (brincidofovir) has provided the United States government with a second therapeutic option to ensure the federal government’s readiness for a potential smallpox emergency.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority
Deal Size: $374.5 million Upfront Cash: $238.0 million
Deal Type: Agreement August 29, 2022
Details:
Chimerix signed a contract agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolutions.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Public Health Agency of Canada
Deal Size: $25.3 million Upfront Cash: Undisclosed
Deal Type: Agreement June 24, 2022
Details:
Chimerix expects to promptly provide treatment courses of TEMBEXA (brincidofovir) equivalent to the total value of the procurement contract. Execution of this contract will be the responsibility of Chimerix.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emergent BioSolutions
Deal Size: $9.3 million Upfront Cash: Undisclosed
Deal Type: Agreement June 23, 2022
Details:
TEMBEXA (brincidofovir), is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emergent BioSolutions
Deal Size: $325.0 million Upfront Cash: $225.0 million
Deal Type: Acquisition May 16, 2022
Details:
Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
